193 related articles for article (PubMed ID: 28712622)
21. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
22. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
Peinemann F; Labeit A
J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
[TBL] [Abstract][Full Text] [Related]
23. Implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
[TBL] [Abstract][Full Text] [Related]
24. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
25. A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?
Dintsios CM
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):283-297. PubMed ID: 33999735
[TBL] [Abstract][Full Text] [Related]
26. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
27. Implementation of Value-based Pricing for Medicines.
Jommi C; Armeni P; Costa F; Bertolani A; Otto M
Clin Ther; 2020 Jan; 42(1):15-24. PubMed ID: 31882225
[TBL] [Abstract][Full Text] [Related]
28. Determinants of Orphan Drug Prices in Germany.
Worm F; Dintsios CM
Pharmacoeconomics; 2020 Apr; 38(4):397-411. PubMed ID: 31903523
[TBL] [Abstract][Full Text] [Related]
29. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
Kleining K; Laufenberg J; Thrun P; Ehlert D; Wasem J; Bartol A
Health Econ Policy Law; 2023 Aug; ():1-18. PubMed ID: 37577932
[TBL] [Abstract][Full Text] [Related]
30. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
31. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
Danzon PM
Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
[TBL] [Abstract][Full Text] [Related]
32. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.
Naidoo K; Suleman F
S Afr Med J; 2021 Apr; 111(5):444-447. PubMed ID: 34852886
[TBL] [Abstract][Full Text] [Related]
34. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
35. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
36. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.
Schwander B; Banz K; Kaier K; Walzer S
Health Policy; 2014 Sep; 117(3):334-44. PubMed ID: 25059744
[TBL] [Abstract][Full Text] [Related]
38. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs.
Skipka G; Wieseler B; Kaiser T; Thomas S; Bender R; Windeler J; Lange S
Biom J; 2016 Jan; 58(1):43-58. PubMed ID: 26134089
[TBL] [Abstract][Full Text] [Related]
39. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
40. Benefit assessment in Germany: implications for price discounts.
Theidel U; von der Schulenburg JM
Health Econ Rev; 2016 Dec; 6(1):33. PubMed ID: 27485438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
